Elismetrep
Investigational oral TRPM8 blocker for acute migraine
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Elismetrep (K-304) is TriGemX Bio's lead investigational therapy, an oral TRPM8 channel blocker being developed for the acute treatment of migraine. Company announcements describe initiation of Phase 3 clinical trials.
- Website
- trigemxbio.com
- Added via
- web
- Ownership
- unclaimed
Where to go
Product details
- Product kind
- Other